TW200722421A - Azole derivatives as inhibitors of lipases and phospholipases - Google Patents

Azole derivatives as inhibitors of lipases and phospholipases

Info

Publication number
TW200722421A
TW200722421A TW095113710A TW95113710A TW200722421A TW 200722421 A TW200722421 A TW 200722421A TW 095113710 A TW095113710 A TW 095113710A TW 95113710 A TW95113710 A TW 95113710A TW 200722421 A TW200722421 A TW 200722421A
Authority
TW
Taiwan
Prior art keywords
phospholipases
lipases
inhibitors
azole derivatives
azole
Prior art date
Application number
TW095113710A
Other languages
English (en)
Inventor
Gerhard Zoller
Stefan Petry
Guenter Mueller
Hubert Heuer
Norbert Tennagels
Original Assignee
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36694158&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TW200722421(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland
Publication of TW200722421A publication Critical patent/TW200722421A/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/20—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
    • C07D275/04—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
TW095113710A 2005-04-20 2006-04-18 Azole derivatives as inhibitors of lipases and phospholipases TW200722421A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102005018389A DE102005018389A1 (de) 2005-04-20 2005-04-20 Azolderivate als Inhibitoren von Lipasen und Phospholipasen

Publications (1)

Publication Number Publication Date
TW200722421A true TW200722421A (en) 2007-06-16

Family

ID=36694158

Family Applications (1)

Application Number Title Priority Date Filing Date
TW095113710A TW200722421A (en) 2005-04-20 2006-04-18 Azole derivatives as inhibitors of lipases and phospholipases

Country Status (20)

Country Link
US (1) US8921404B2 (zh)
EP (1) EP1874741A1 (zh)
JP (1) JP2008536884A (zh)
KR (1) KR20080004501A (zh)
CN (1) CN101160293A (zh)
AR (1) AR053228A1 (zh)
AU (1) AU2006237127A1 (zh)
BR (1) BRPI0608495A2 (zh)
CA (1) CA2606301A1 (zh)
DE (1) DE102005018389A1 (zh)
IL (1) IL186635A0 (zh)
MA (1) MA29393B1 (zh)
MX (1) MX2007012732A (zh)
MY (1) MY142441A (zh)
NO (1) NO20075938L (zh)
NZ (1) NZ562694A (zh)
RU (1) RU2414458C2 (zh)
TW (1) TW200722421A (zh)
WO (1) WO2006111321A1 (zh)
ZA (1) ZA200707929B (zh)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2009001043A (es) 2006-08-08 2009-02-06 Sanofi Aventis Imidazolidina-2,4-dionas sustituidas con arilaminoarilalquilo, procedimiento para preparalas, medicamentos que comprenden estos compuestos y su uso.
AU2008235071A1 (en) 2007-04-05 2008-10-16 Sanofi-Aventis 5-oxo-isoxazoles as inhibitors of lipases and phospholipases
WO2008122352A1 (de) 2007-04-05 2008-10-16 Sanofi-Aventis Imidazolidin-carbonsäureamid-derivate als inhibitoren von lipasen und phospholipasen
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US8470841B2 (en) 2008-07-09 2013-06-25 Sanofi Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
JP5605844B2 (ja) 2008-10-17 2014-10-15 塩野義製薬株式会社 血管内皮リパーゼ阻害活性を有する酢酸アミド誘導体
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
GB2466121B (en) * 2008-12-15 2010-12-08 Amira Pharmaceuticals Inc Antagonists of lysophosphatidic acid receptors
ES2443016T3 (es) 2009-08-26 2014-02-17 Sanofi Nuevos hidratos cristalinos de fluoroglicósidos heteroaromáticos, productos farmacéuticos que comprenden estos compuestos, y su empleo
CA2784710A1 (en) 2009-12-15 2011-06-23 Shionogi & Co., Ltd. Oxadiazole derivative having endothelial lipase inhibitory activity
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
US8933024B2 (en) 2010-06-18 2015-01-13 Sanofi Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
CN103298469A (zh) 2010-08-31 2013-09-11 首尔大学校产学协力财团 PPARδ激动剂的胎儿重编程的用途
US8710050B2 (en) 2011-03-08 2014-04-29 Sanofi Di and tri- substituted oxathiazine derivatives, method for the production, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
US8871758B2 (en) 2011-03-08 2014-10-28 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
US8828995B2 (en) 2011-03-08 2014-09-09 Sanofi Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
EP2766349B1 (de) 2011-03-08 2016-06-01 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2012120054A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US9321787B2 (en) * 2011-07-07 2016-04-26 Sanofi Carboxylic acid derivatives having an oxazolo[5,4-d]pyrimidine ring
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
KR20180048798A (ko) * 2015-08-27 2018-05-10 오클랜드 유니서비시즈 리미티드 트립토판 디옥시게나제 (ido1 및 tdo)의 억제제 및 치료에서 이들의 용도

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030114420A1 (en) * 2000-06-28 2003-06-19 Salvati Mark E. Fused cyclic modulators of nuclear hormone receptor function
WO2002060422A2 (en) * 2001-02-02 2002-08-08 Pfizer Limited Treatment of diabetes mellitus using vardenafil
WO2003005184A2 (en) 2001-07-04 2003-01-16 Akodi S.A. Web windowed graphical user interface
JP2003033007A (ja) 2001-07-09 2003-01-31 Sanyo Electric Co Ltd チャージポンプ回路の制御方法
JP2005518376A (ja) * 2001-12-14 2005-06-23 ノボ　ノルディスク　アクティーゼルスカブ 化合物およびホルモン感受性リパーゼの活性を低下させるためのその使用
WO2004058749A1 (en) 2002-12-18 2004-07-15 Vertex Pharmaceuticals Incorporated Benzisoxazole derivatives useful as inhibitors of protein kinases
WO2004094393A1 (en) * 2003-04-01 2004-11-04 Eli Lilly And Company Phospholipase inhibitors
WO2004094394A1 (en) * 2003-04-01 2004-11-04 Eli Lilly And Company Benzisothiazol-3-one-carboxylic acid amides as phospholipase inhibitors
EP1746991A2 (en) * 2004-03-16 2007-01-31 Janssen Pharmaceutica N.V. Daao inhibiting benzisoxazoles for treating mental disorders
TW200633990A (en) * 2004-11-18 2006-10-01 Takeda Pharmaceuticals Co Amide compound

Also Published As

Publication number Publication date
MY142441A (en) 2010-11-30
AR053228A1 (es) 2007-04-25
KR20080004501A (ko) 2008-01-09
CA2606301A1 (en) 2006-10-26
RU2414458C2 (ru) 2011-03-20
MA29393B1 (fr) 2008-04-01
RU2007142657A (ru) 2009-05-27
ZA200707929B (en) 2008-12-31
JP2008536884A (ja) 2008-09-11
DE102005018389A1 (de) 2006-10-26
AU2006237127A1 (en) 2006-10-26
WO2006111321A1 (de) 2006-10-26
CN101160293A (zh) 2008-04-09
EP1874741A1 (de) 2008-01-09
IL186635A0 (en) 2008-01-20
US8921404B2 (en) 2014-12-30
US20080090867A1 (en) 2008-04-17
NZ562694A (en) 2010-05-28
BRPI0608495A2 (pt) 2010-01-05
MX2007012732A (es) 2008-03-14
NO20075938L (no) 2007-11-19

Similar Documents

Publication Publication Date Title
TW200722421A (en) Azole derivatives as inhibitors of lipases and phospholipases
TW200730513A (en) Carbamoylbenzotriazole derivatives as inhibitors of lipases and phospholipases
TW200728285A (en) Diacylindazole derivatives as inhibitors of lipases and phospholipases
TW200800987A (en) Triazolopyridine derivatives as inhibitors of lipases and phospholipases
MY143407A (en) Indazole derivatives as inhibitors of hormone sensitive lipase
MX2009010485A (es) Derivados de imidazolidinacarboxamida como inhibidores de lipasas y fosfolipasas.
MX2010006799A (es) Benzofuropirimidinonas como inhibidores de la proteina cinasa.
TN2010000203A1 (en) Beta-lactamase inhibitors
MY161991A (en) Proteasome inhibitors
MX2009008798A (es) Derivados de iminipiridina y sus usos como microbicidas.
MX2007003546A (es) Derivados de indozolona como inhibidores de 11-beta- hidroxiesteroide-deshidrogenasa.
UA104731C2 (ru) Ингибиторы р38 мар-киназ
SG161318A1 (en) Heterocyclic inhibitors of mek and methods of use thereof
WO2007115821A3 (en) Organic compounds
NO20084418L (no) Azolopyridin-3-on derivater som inhibitorer av endoteliallipase
MY166653A (en) Derivatives of 1-amino-2-cyclobutylethylboronic acid
MA32776B1 (fr) Inhibiteurs de l'akt et de la p70 s6 kinase
MY155719A (en) 2-benzylpyridazinone derivatives as met kinase inhibitors
GEP20156242B (en) 2-arylimidazole derivatives as pde10a enzyme inhibitors
TW200716653A (en) Azolopyridin-2-one derivatives as inhibitors of lipases and phospholipases
TW200716577A (en) Benzooxazol-2-one derivatives as inhibitors of lipases and phospholipases
MX2009004017A (es) Usos de los compuestos carboxi-amido triazol y sus sales.
MX2009010483A (es) 5-oxoisoxazoles como inhibidores de lipasas y fosfolipasas.
IL205696A0 (en) Heterocyclic derivatives, compositions comprising the same and uses thereof
TW200716581A (en) Benzothiazol-2-one derivatives as inhibitors of lipases and phospholipases